Moderna, Inc. (NASDAQ: MRNA) reported second quarter 2023 earnings results today.
Total revenue dropped to $344 million from $4.7 billion in the same period last year, mainly due to a decrease in sales of the company’s COVID-19 vaccine.
Net loss was $1.4 billion, or $3.62 per share, compared to net income of $2.2 billion, or $5.24 per share, last year.
Product sales were $293 million, down 94% compared to last year, mainly due to lower sales volume. The company reported $0.3 billion in COVID-19 vaccine sales in Q2.
For FY2023, the company is expecting COVID-19 sales of $6-8 billion, dependent on US vaccination rates.
Most Popular
Colgate-Palmolive (CL) Q3 2024 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its third quarter 2024 earnings results today. Net sales increased 2.4% year-over-year to $5 billion. Organic sales grew 6.8%. Net income attributable to Colgate-Palmolive Company was $737
Key takeaways from Southwest Airlines’ (LUV) Q3 2024 earnings report
Shares of Southwest Airlines Co. (NYSE: LUV) were down over 4% on Thursday. The stock has gained 4% over the past three months. The airline reported its earnings results for
HOG Earnings: A snapshot of Harley-Davidson’s Q3 2024 results
Motorcycle manufacturer Harley-Davidson (NYSE: HOG) Thursday reported a sharp fall in sales and net profit for the third quarter of 2024 amid weak demand. Consolidated net income declined to $119
